AlphAIalphai — Financial news for AI agents
Stock TitanFEB 232 min read$ANGO

Hear AngioDynamics CEO Jim Clemmer live at Leerink healthcare conference

AngioDynamics (NASDAQ: ANGO) President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 1:40 p.m. ET. A live webcast of the presentation will be available on the company's website. AngioDynamics specializes in medical technology for vascular systems, cancer treatment, and patient quality of life.

Original reporting
Stock Titan
Published Feb 23, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 23, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$ANGO
Neutral
medium confidence
Mentioned
$ANGO
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$ANGONeutralMed
01

Why it matters

The event could serve as a catalyst for stock appreciation if new initiatives or positive updates are announced.

02

Market read

The event is highly relevant for investors interested in healthcare and medical technology stocks, especially those holding or considering ANGO shares.

03

What to watch

Market sentiment could be cautious due to broader healthcare sector uncertainties or macroeconomic factors unrelated to the event.

Timing: High; event scheduled for March 9, 2026, with potential immediate market reaction.

Background

AngioDynamics is a key player in medical technology, with a focus on vascular and cancer treatments. The upcoming CEO presentation is a strategic communication event.

Company-level read

Ticker impact

$ANGONeutralMedium confidence
Context

The news pertains directly to AngioDynamics, as the company's CEO will present at a major healthcare conference, indicating potential upcoming developments.

Expected impact

Moderate upward movement expected within 1-2 weeks post-event.

Evidence & confidence

While CEO presentations can lead to positive sentiment and stock appreciation, the impact depends on the content of the presentation and market reception.

Market effects

Sector

Potential positive impact on the medical technology sector, especially companies involved in vascular and cancer treatment.

Regional

Primarily affecting U.S. markets, given the company's location and conference venue.

Global

Limited; the event's impact is expected to be localized to sector and regional markets.

Counterpoint

What could challenge this read

The presentation may reveal challenges or lack of significant updates, leading to minimal or negative stock movement.

Key entities

  • Company
    AngioDynamics

    A medical technology company specializing in vascular systems and cancer treatment.

  • CEO
    Jim Clemmer

    President and CEO of AngioDynamics, scheduled to present at the conference.

Read at source← All news

Related articles

AUG 11
$ANGOMed

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.

yahoo.com4 min
JUL 21
$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

yahoo.com7 min
AUG 29
$CWENMedAI 8/10

Nobody's Talking About This Energy Company, but It's Quietly Signing the Power Deals Feeding the AI Build-Out

Clearway Energy (NYSE:CWEN) signed a 1.2 GW deal with Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) for renewable power, with projects starting in 2027-2028. The company also secured PPAs for legacy wind farms, doubling prior pricing. Clearway expects 5%-8%+ CAFD growth through 2030, with potential for further growth via data center power investments. It offers a high-yield dividend and stable returns, contrasting with more volatile AI power plays.

yahoo.com3 min